ISTA Pharmaceuticals announced the results from its Phase 2 trial of Remura (bromfenac ophthalmic solution) for the treatment of dry eye disease. The study achieved statistical significance in the primary endpoint of the objective sign of conjunctival staining (p<0.001) as compared to baseline. The study also achieved statistical significance on the objective sign of corneal staining (p<0.01) as compared to baseline. In addition, patients achieved statistically significant improvements in subjective symptoms measured by the Ocular Surface Disease Index (OSDI) (p<0.001) and in patients’ most bothersome ocular symptoms. Patients treated with Remura maintained the improvements in the signs and symptoms of dry eye disease for 10 days after discontinuing treatment, which was evaluated at the time of the follow up visit.
Remura (bromfenac ophthalmic solution for dry eye) is a sterile, topical non-steroidal anti-inflammatory (NSAID) compound under investigation for use as an ophthalmic agent to alleviate the signs and symptoms of dry eye disease.
For more information call (949) 788-6000 or visit www.istavision.com.